Health and Fitness Health and Fitness
Fri, June 24, 2011
[ 01:05 AM ] - Market Wire
FDA Advisory Committee Strongly Recommends Approv .. FIRAZYR® (icatibant) for the Treatment of Acute
[ 01:05 AM ] - Market Wire
China-Biotics, Inc. Receives NASDAQ Delisting Notification
Thu, June 23, 2011
[ 04:53 PM ] - Market Wire
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
[ 03:42 PM ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Announces Investigation of SeraCare Life Sciences, Inc.
[ 03:00 PM ] - Market Wire
Mylan Launches First Generic Version of Entocort EC® Capsules
[ 02:30 PM ] - Market Wire
LABOPHARM ANNOUNCES REDUCTION OF ANGELINI LABOPHARM';S OLEPTRO&;#8482; SALES FORCE
[ 01:24 PM ] - Market Wire
Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend
[ 01:01 PM ] - Market Wire
Humana Military Healthcare Servicesa? Ray Pryor n .. fficer of the Yeara? by Louisville Business First
[ 09:38 AM ] - Market Wire
Medtronic Board Increases Cash Dividend by Eight Percent; Increases Share Repurchase Plan
[ 09:34 AM ] - Market Wire
Aetna Helps Members in North Dakota Affected by Floods
[ 07:55 AM ] - Market Wire
Akorn, Inc. Announces Second Quarter 2011 Earnings Release and Conference Call Information
[ 05:44 AM ] - Market Wire
Microbix Biosystems Receives Notice of Allowed Pa .. ation for LumiSort&;#8482; Livestock Semen Sexing
[ 05:43 AM ] - Market Wire
Invacare Corporation Named One of the Top Workplaces in Northeast Ohio
[ 05:42 AM ] - Market Wire
Immunovaccine Announces Results of 2011 AGM
[ 04:30 AM ] - Market Wire
Fire Department Seeks Federal Funding for Firefig .. ge Hearta?s Sudden Cardiac Arrest Diagnostic Test
[ 04:00 AM ] - Market Wire
Repligen Receives U.S. Fast Track Designation and .. oduct Recommendation for RG3039 for Spinal Muscul
[ 01:04 AM ] - Market Wire
USANA Health Sciences and WTA Launch "Ace Out Hunger" Program
Wed, June 22, 2011
[ 11:00 PM ] - Market Wire
St. Jude Medical presenta datos de un ensayo clni .. los beneficios de la neuromodulacin para la migra
[ 11:00 PM ] - Market Wire
St. Jude Medical comunica i dati di una speriment .. he dimostra i benefici della neuromodulazione per
[ 11:00 PM ] - Market Wire
St. Jude Medical maakt gegevens van gerandomiseer .. die het voordeel aantonen van neuromodulatie voor
[ 11:00 PM ] - Market Wire
St. Jude Medical verffentlicht Ergebnisse einer r .. die: Vorteile von Neuromodulation bei chronischer
[ 03:04 PM ] - Market Wire
Tornier Announces Launch of the AequalisTM Ascend .. nt System at the 28th Annual San Diego Shoulder C
[ 02:00 PM ] - Market Wire
New England Journal of Medicine Publishes Data Fr .. Studies of INCIVEKa" (telaprevir) in Hepatitis C
[ 09:29 AM ] - Market Wire
NanoViricides, Inc. to Present at OneMedForum NY .. e for Emerging Healthcare and Life Science Compan
[ 09:25 AM ] - Market Wire
NIS Holdings, Acquires Alpha Card Technology, Inc .. tion Will Add Up to 43 Million USD to Bottom Line
[ 05:30 AM ] - Market Wire
ImmunoCellular Therapeutics to Present at 2nd World Cancer Vaccines Summit
[ 05:30 AM ] - Market Wire
Health Net Earns Webby Distinction for Second Consecutive Year
[ 05:00 AM ] - Market Wire
Crystal IS Appoints Leading Entrepreneur to Board of Directors
[ 05:00 AM ] - Market Wire
Ligand to Advance Clinical Development of Captiso .. pylene Glycol-Free Melphalan for Multiple Myeloma
[ 04:12 AM ] - Market Wire
La Comisin Europea aprueba la inclusin del estatu .. mo factor de riesgo PML en la etiqueta de TYSABRI

La Comisin Europea aprueba la inclusin del estatus de anticuerpo anti- JCV como factor de riesgo PML en la etiqueta de TYSABRI


Published on 2011-06-22 04:26:03 - Market Wire
  Print publication without navigation


WESTON, Massachussets & DUBLIN--([ BUSINESS WIRE ])--[ Biogen Idec ] (NASDAQ: BIIB) y [ Elan Corporation ], plc (NYSE: ELN) han comunicado que la Comisin Europea ha aprobado la inclusin del estatus de anticuerpo anti.-JCV como factor adicional para estratificar los pacientes con riesgo de desarrollar PML (eucoencefalopata multifocal progresiva) en el resumen de las caractersticas de producto (SmPC) de [ TYSABRI ]® (natalizumab) en la UE. Adems, como parte del proceso de revisin estndar, la Comisin Europea ha determinado que la calidad, seguridad y eficacia de TYSABRI continan siendo adecuadamente demostradas y ha renovado la autorizacin de marketing para cinco aos en la Unin Europea.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources